ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 14, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 14, 2011
News
FDA Publishes Guidance for Preventing Cross-Contamination
By Erik Greb
FDA recently published guidance for preventing the cross-contamination of finished pharmaceuticals and active pharmaceutical ingredients with nonpenicillin beta-lactam antibiotics.
Merck Forms Joint Venture with Sun Pharmaceutical
By Patricia Van Arnum
Merck & Co. has formed a joint venture with the Mumbai-based specialty pharmaceutical company Sun Pharmaceutical Industries to develop, manufacture, and commercialize new combinations and formulations of branded generic drugs in emerging markets.
J&J Announces Settlement for Corrupt Practices
By Stephanie Sutton
Johnson and Johnson (J&J) has agreed to pay more than $77 million after being charged for violations of the US Foreign Corrupt Practices Act, which include bribing public doctors in several European countries and paying kickbacks to illegally obtain business in Iraq.
A Record Number of Therapies for Cancer Currently in Development
By Amy Ritter
Nearly 900 therapies for the treatment, diagnosis or prevention of cancer are currently in development, according to a report released by PhRMA.
Regulatory Roundup: FDA Released Draft Guidance for Industry on Safety Labeling Changes
FDA Released Draft Guidance for Industry on Safety Labeling Changes.
Week of Apr. 14, 2011: Company and People Notes: Alynlyam forms drug-delivery pact with the University of British Columbia; Linda S. Mayer Joins Schott North America; and More.
Alynlyam forms drug-delivery pact with the University of British Columbia; Linda S. Mayer Joins Schott North America; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here